We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ultrasis | ULT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.095 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.095 | 0.095 |
| Top Posts |
|---|
Posted at 25/8/2023 23:28 by doomsday_man Lots of posts here considering this company has not existed for years.It must be a private messaging service. If I am wrong, when did ULT last make a profit?. |
Posted at 19/7/2023 10:44 by woollworth Convincing as Doris humph, get jabbed 96% safe stop the spread don't kill granny BS.Could be a short term profit but hold and lose shirt, think about ult BS, quote we have public sector contracts, go into profit, I invested more and lost the lot. Not forgetting SOH has lost over 90% of investors value, from high. |
Posted at 27/6/2023 03:23 by 2pigshit And me wull getting an Audi a6 hybrid ps sdy dividend 8.9% |
Posted at 15/6/2023 14:57 by woollworth London has opti level at 2.55, whats wrong, this stock is finished imo, been going down for a year, turned into soh's gravy train, same as ult imo.I'm sorry to say. |
Posted at 19/5/2023 20:43 by woollworth humph just checked the price still dropping below, 10p at close, terrible stock aka SOHs gravy train, defo ult two...Wish I dumped at 15p, looks like we have another junk stock, to add to the rest. Bad news on results 5p or less imo. Half decent results doubtful 11.5p imo. Decent news 16p ish imo. Expecting the worse because of pathetic track record and the fact soh employed more staff adding to loss, rather than profit, as he boasted/stated, |
Posted at 06/2/2023 14:25 by humphries1 Hi wooly he uses ADVFN but he cant get any were using ULT it dont go any place for him |
Posted at 06/2/2023 10:52 by humphries1 I wont sneeze wooly i promise, LOL.By thee way wooly a mate of mine tried to join us on this thread but for some reason he cant any ideas ?, he put ULT in and didnt get anywere |
Posted at 17/1/2023 22:57 by woollworth All well and good from the guild thread but a small rise followed by todays drop and probably tomorrow, ult used to post partnership here there and everywhere, we now know know it was BS.Opti need to sell massive amounts of their gear to cover office and all the staff, vehicles etc. The new employees will be on big numbers, our numbers are constantly falling around 90%, while they maintain 100% of their salary etc. If we ever see 50p again?, I may start believing. |
Posted at 31/3/2022 08:56 by humphries1 hi wooly more news from OPTI31 March 2022 OptiBiotix Health plc ("OptiBiotix" or the "Company") Admission of ProBiotix Health plc to AQSE Growth Market OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, high cholesterol, diabetes and skin care, a nnounces the admission of its former subsidiary, ProBiotix Health plc (AQSE: PBX), onto the AQSE Growth Market. As part of the Admission, ProBiotix Health plc ("ProBiotix" or "PBX") has raised GBP2.5 million through a placing and subscription of 11,904,762 Ordinary Shares at a price of 21p per share. A total of 121,666,666 ordinary shares of 0.05p each in PBX ("Ordinary Shares") will be admitted to trading on the Access Segment of the AQSE Growth Market ("Admission") today valuing ProBiotix at approximately GBP25.5m. PBX has a unique strain of Lactobacillus plantarum trademarked as LPLDL which three clinical studies published in peer reviewed journals have shown statistically significant changes to clinically important cardiovascular risk including total cholesterol, LDL (bad) cholesterol, and Apolipoprotein B. The company also has six publications showing LPLDL's mechanism of action and 27 patents and 22 trademarks protecting its commercial interests, and FDA GRAS which allows the use of LPLDL in food products. OptiBiotix recently announced (RNS: 28 February 2022) that preliminary unaudited results for PBX for the year ended 31 December 2021, indicated total sales of GBP1.1 million. Distribution The Company is pleased to confirm that OptiBiotix shareholders on the register as at close of business on 25 March 2022 ("Record Date") will receive 0.554673 ProBiotix share for every one OptiBiotix ordinary share held. Entitlements will be rounded down to the nearest whole number of PBX Shares. The legal title to the Dividend Shares will be held by Global Prime Partners Nominees Ltd acting as nominee on behalf of each of the Qualifying Shareholders ("Nominee") and an 'omnibus' share certificate in respect of the Dividend Shares. The Nominee will hold the Dividend Shares on trust for each of the Qualifying Shareholders for a minimum period of nine months following admission to trading on AQSE of the issued share capital of ProBiotix ("Lock-up Period"). The Lock-up Period is intended to contribute to the creation of an orderly market in ProBiotix Health's shares for a period after admission to trading. At the end of the Lock-up Period, the Nominee will be entitled to execute stock transfer forms to transfer the legal title to the Dividend Shares to each Qualifying Shareholder (as appropriate). CREST Shareholders should note that, pursuant to the Dividend, the ProBiotix shares will be transferred to the Nominee to be held on trust for the benefit of the OptiBiotix Shareholders. Accordingly, the automated CREST market claims process will not be available in respect of the dividend in specie entitlements to ProBiotix shares. Any market claims will therefore need to be agreed bi-laterally between affected Participants for settlement following the transfer of the Probiotix shares from the Nominee to the entitled OptBiotix Shareholders in January 2023. Following the distribution in specie of Ordinary Shares to its shareholders, OptiBiotix remains interested in 53,533,333 Ordinary Shares, representing approximately 44% of the issued share capital of ProBiotix Health plc. Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix has been really pleased with the development of its ProBiotix Health business and now believes that the scale of the opportunities offered by LPLDL, particularly in dairy and pharma which require specialist skill sets, may best be realised by a separate listing. The separate listing and fundraise allows ProBiotix to accelerate commercial progress and grow direct to consumer product sales, and expand into key markets like dairy and pharma. The admission to AQSE materialises the value of Probiotix as a valuable asset to OptiBiotix shareholders who benefit from a dividend in species and the potential for substantial future value enhancement of a subsidiary." EDIT wooly thats 2 assets that we have now, thats SBTX and PBX |
Posted at 31/3/2022 08:49 by humphries1 hi wooly news.by the way wooly i am taking CHOLBIOME X3 a OPTI product for bad cholesterol been taking 15 days so far, going to try them for 3 months see what happens. 31 March 2022 OptiBiotix Health plc ("OptiBiotix" or the "Company") Admission of ProBiotix Health plc to AQSE Growth Market OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, high cholesterol, diabetes and skin care, a nnounces the admission of its former subsidiary, ProBiotix Health plc (AQSE: PBX), onto the AQSE Growth Market. As part of the Admission, ProBiotix Health plc ("ProBiotix" or "PBX") has raised GBP2.5 million through a placing and subscription of 11,904,762 Ordinary Shares at a price of 21p per share. A total of 121,666,666 ordinary shares of 0.05p each in PBX ("Ordinary Shares") will be admitted to trading on the Access Segment of the AQSE Growth Market ("Admission") today valuing ProBiotix at approximately GBP25.5m. PBX has a unique strain of Lactobacillus plantarum trademarked as LPLDL which three clinical studies published in peer reviewed journals have shown statistically significant changes to clinically important cardiovascular risk including total cholesterol, LDL (bad) cholesterol, and Apolipoprotein B. The company also has six publications showing LPLDL's mechanism of action and 27 patents and 22 trademarks protecting its commercial interests, and FDA GRAS which allows the use of LPLDL in food products. OptiBiotix recently announced (RNS: 28 February 2022) that preliminary unaudited results for PBX for the year ended 31 December 2021, indicated total sales of GBP1.1 million. Distribution The Company is pleased to confirm that OptiBiotix shareholders on the register as at close of business on 25 March 2022 ("Record Date") will receive 0.554673 ProBiotix share for every one OptiBiotix ordinary share held. Entitlements will be rounded down to the nearest whole number of PBX Shares. The legal title to the Dividend Shares will be held by Global Prime Partners Nominees Ltd acting as nominee on behalf of each of the Qualifying Shareholders ("Nominee") and an 'omnibus' share certificate in respect of the Dividend Shares. The Nominee will hold the Dividend Shares on trust for each of the Qualifying Shareholders for a minimum period of nine months following admission to trading on AQSE of the issued share capital of ProBiotix ("Lock-up Period"). The Lock-up Period is intended to contribute to the creation of an orderly market in ProBiotix Health's shares for a period after admission to trading. At the end of the Lock-up Period, the Nominee will be entitled to execute stock transfer forms to transfer the legal title to the Dividend Shares to each Qualifying Shareholder (as appropriate). CREST Shareholders should note that, pursuant to the Dividend, the ProBiotix shares will be transferred to the Nominee to be held on trust for the benefit of the OptiBiotix Shareholders. Accordingly, the automated CREST market claims process will not be available in respect of the dividend in specie entitlements to ProBiotix shares. Any market claims will therefore need to be agreed bi-laterally between affected Participants for settlement following the transfer of the Probiotix shares from the Nominee to the entitled OptBiotix Shareholders in January 2023. Following the distribution in specie of Ordinary Shares to its shareholders, OptiBiotix remains interested in 53,533,333 Ordinary Shares, representing approximately 44% of the issued share capital of ProBiotix Health plc. Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix has been really pleased with the development of its ProBiotix Health business and now believes that the scale of the opportunities offered by LPLDL, particularly in dairy and pharma which require specialist skill sets, may best be realised by a separate listing. The separate listing and fundraise allows ProBiotix to accelerate commercial progress and grow direct to consumer product sales, and expand into key markets like dairy and pharma. The admission to AQSE materialises the value of Probiotix as a valuable asset to OptiBiotix shareholders who benefit from a dividend in species and the potential for substantial future value enhancement of a subsidiary." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
